Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker ... It plans to submit orforglipron for FDA approval for obesity in Q4, and for type 2 diabetes in the first half of 2026.

It plans to submit orforglipron for FDA approval for obesity in Q4, and for type 2 diabetes ... On the day of Eli Lilly's earnings report, CVS Health announced that its pharmacy benefit manager ...

Hims & Hers Health, Inc. navigates strong growth and partnerships despite rising competitive risks. Click here to read an ...

Read here for an update on key Q1 2025 portfolio moves by Duquesne Family Office. Get insights into top holdings, new ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... number of billionaire investors, updated as of Q4 2024. All of these billionaire investors are founders ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... with the highest number of hedge fund holders as of Q4 2024. We sourced the hedge fund sentiment data from ...

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after the ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...